Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Christopher Bredeson, Silvia Montoto(Queen Mary University of London), Steven Le Gouill(Inserm), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Paul A. Carpenter(Fred Hutch Cancer Center), Stephen Robinson(Intel (United States)), Alex F. Herrera(City of Hope), Jonathan W. Friedberg(University of Rochester), Mazyar Shadman(University of Washington), Paolo Corradini(Gruppo di Ricerca Geriatrica), Alison J. Moskowitz, Timothy S. Fenske(Medical College of Wisconsin), David J. Inwards(Mayo Clinic), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Julie M. Vose(University of Nebraska Medical Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Peter Dreger(Heidelberg University), Nishitha Reddy(Vanderbilt University), Christian Gisselbrecht(Institut Universitaire de France), Bipin N. Savani(Vanderbilt University Medical Center), Ambuj Kumar(University of South Florida), Martin Dreyling(LMU Klinikum), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Syed A. Abutalib(Cancer Treatment Centers of America), Sonali M. Smith(University of Chicago)
Cited by 57
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k